Digital Pathway - The Disproportionate Burden of Atrial Fibrillation in High-Risk African American Patients with Cardiometabolic Comorbidities
Atrial fibrillation (AF) remains underdiagnosed, particularly in African American patients with a high burden of AF risk factors, such as those with cardiometabolic comorbidities. Additionally, stroke prevention in these patients is suboptimal, with suboptimal application of evidence-based therapies and guidelines, including the suboptimal use of direct oral anticoagulants (DOACs).
During this activity, experts will discuss important considerations that can help address these disparities, including appropriate screening, treatment, as well as addressing the underlying social determinants of health that greatly contribute to the suboptimal care of African American patients with AF. The design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, organized into different segments to facilitate learning.
US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), sleep specialists, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
After completing this activity, the participant should be better able to:
- Recognize the prevalence, burden, and potential increased risk of undiagnosed AF in high-risk African American patients.
- Select screening criteria and emerging technological approaches in order to timely diagnose AF in African Americans.
- Summarize recent evidence with DOACs in cardiometabolic patients with AF, as well as race-specific efficacy and safety data.
- Identify individualized treatment regimens for stroke prevention in high-risk African American patients with atrial fibrillation and cardiometabolic comorbidities based on current guidelines, RCT and real-world evidence, as well as patient-specific factors.
Keith C. Ferdinand, MD, FACC, FAHA (Chair)
Professor of Medicine, Tulane University School of Medicine
New Orleans, LA
Dr. Ferdinand discloses the following:
Consulting Fee (e.g., Advisory Board): Amgen, Novartis, Lilly, Janssen, Boehringer Ingelheim
Larry R. Jackson, II, MD, MHSc
Assistant Professor of Medicine, Duke University Medical Center/Duke Clinical Research Institute
Dr. Jackson discloses the following:
Consulting Fee (e.g., Advisory Board): Biosense Webster Inc., Johnson and Johnson Inc, Pfizer Inc
Honoraria: Health Monitor, Zoll Life Vest
Speakers’ Bureau: Medtronic Inc
Laura Ross, PA-C, CLS, AACC
Director, Heart Disease Prevention Clinic, Park Nicollet Heart and Vascular Center
St. Louis Park, MN
Ms. Ross has nothing to disclose.
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Janssen Scientific Affairs, LLC.
JOINT PROVIDERSHIP STATEMENT
This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point amount and Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
NURSING CONTINUING EDUCATION
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACIST ACCREDITATION STATEMENT
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): 0530-9999-22-242-H01-P.
This is a knowledge-based activity.
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DIETITIAN ACCREDITATION STATEMENT
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012
GLOBAL CONTACT INFORMATION
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org..
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The planners and managers have the following relevant financial relationships with ineligible companies:
|Name of Planner or Manager||Reported Financial Relationship|
|Rhys Williams, MSN, FNP-C, RN||Nothing to disclose.|
|Kristin Delisi, NP||Nothing to disclose.|
|Amanda Turner MS, RDN, CSSD||Nothing to disclose.|
|Conor Hughes||Nothing to disclose.|
|Andrea Funk||Nothing to disclose.|
|Liddy Knight||Nothing to disclose.|
|Ashley Cann||Nothing to disclose.|
|Lauren Sinclair||Nothing to disclose.|
|Karin McAdams||Nothing to disclose.|
|Shpetim Karandrea, PhD||Nothing to disclose.|
|Neha Agarwal, PhD||Nothing to disclose.|
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
This activity is complimentary and available during the period April 19, 2023 through April 19, 2024. Participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 70% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please contact Global at 303-395-1782 or email@example.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.